NOVARTIS for NOVARTIS
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Feb 1, 2011 | $1,000,000 | Replaced |
| 4th Quarter - Report | Jan 30, 2012 | $1,000,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Free Trade Agreements: - Intellectual Property Provisions in Panama, Colombia, Korea Access to Medicines Global Health Issues
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH HALLER | — |
Copyright/Patent/Trademark CPT
HR 1260 Patent Reform Act of 2009 S 515 Patent Reform Act of 2009 Patent Settlement Legislation
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| MARY L COEN New | — |
| DAVID DRAKE | — |
| JAMES ELKIN | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| BRUCE ANTHONY RUSCIO New | — |
| KATHERINE SOLON | — |
Health Issues HCR
H.R.3200 America's Affordable Health Choices Act of 2009 S.1796 America's Healthy Future Act of 2009 H.R.3962 Affordable Health Care for America Act H.R.3590 Patient Protection and Affordable Care Act H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 HR 1038, S623 - Access to Life-Saving Medicine Act HR 1548 Pathway for Biosimilars Act HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act S 726 - Promoting Innovation and Access to Life-Saving Medicine Act S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Personalized Medicine Public Health Service Act Drug Importation Gene Therapy PDUFA
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| MARY L COEN New | — |
| DAVID DRAKE | — |
| JAMES ELKIN | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| BRUCE ANTHONY RUSCIO New | — |
| KATHERINE SOLON | — |
Medicare/Medicaid MMM
Access to Life Saving Medicines Act Provide Medicare Part B Coverage for Vaccines Covered under Part D Medicaid Coverage of Vaccines HR2 Children's Health Insurance Program Reauthorization Act of 2009 S 275 Children's Health Insurance Program Reauthorization Act of 2009 HR 2800 Imported Food Safety Improvement Act of 2009 Medicare Prescription Drugs and Modernization Act Immunosuppressant Legislation
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| MARY L COEN New | — |
| DAVID DRAKE | — |
| JAMES ELKIN | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| BRUCE ANTHONY RUSCIO New | — |
| KATHERINE SOLON | — |
Budget/Appropriations BUD
HR 1458 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009 S565 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009 Pandemic Influenza Funding FDA Appropriations funding for Generic Drugs HR 7110 Job Creation and Unemployment Relief Act of 2008 HR 1 American Recovery and Reinvetment Act FY 2010 Labor HHS Appropriations Bill - Pandemic Funding, Section 317 Program FY 2010 DoD Appropriations Bill - Transformational Medical Technologies Initiative Pandemic Funding
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| MARY L COEN New | — |
| DAVID DRAKE | — |
| JAMES ELKIN | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| BRUCE ANTHONY RUSCIO New | — |
| KATHERINE SOLON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.